Clinical Trials - June 14, 2022
Lytix Biopharma announces new data
Lytix Biopharma has announced data from its ATLAS-IT-04 trial in patients with metastatic soft tissue sarcoma (STS). The data from this Phase II proof of concept study shows that LTX-315 in combination with Adoptive Cell Therapy (ACT) was able to stabilize the disease in 3 out of 4 fully treated patients in this hard-to-treat patient […]
In a new job - May 25, 2021
Lytix Biopharma strengthens its board of directors
Lytix Biopharma have announced the nomination of four new board members. The four are the Swedish citizens, PhD Marie-Louise Fjällskog and PhD Evelina Vågesjö, the Norwegian citizen Kjetil Hestdal and the US citizen Jayson Rieger. They will all supplement the present board. Read more: Lytix Biopharma prepares for listing on Euronext Growth Oslo “I’m very […]
Clinical Trials - May 10, 2021
Lytix Biopharma announces positive data
Lytix Biopharma has announced promising data results from a phase I study of its lead candidate LTX-315. The findings were published in Clinical Cancer Research. “A major and persistent challenge in today’s cancer treatment is lack of tumor infiltrating T cells in the majority of cancer patients, making it difficult for the immune system to […]
Agreement - April 13, 2021
Lytix Biopharma in agreement with Arctic University of Norway
The company enters into an exclusive license agreement with the university for a class of new drug candidates and forms a strategic partnership with Aurelius Biotherapeutics. Lytix Biopharma, in collaboration with a research team at the Arctic University of Norway (UiT), has developed a new group of drug candidates, which can combat cancer cells through […]
Clinical Trials - January 20, 2021
Lytix Biopharma receives FDA clearance to initiate Phase II study
Lytix Biopharma has announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for LTX-315, an oncolytic molecule in development for various solid tumors. “This is a significant milestone for Lytix Biopharma, as it clears a path for further clinical development towards market approval in the US, […]
Agreement - August 12, 2020
Lytix Biopharma enters milestone agreement
Lytix Biopharma licenses its lead candidate LTX-315, an oncolytic peptide based immunotherapy, to Verrica Pharmaceuticals, for the treatment of dermatologic oncology indications. “With aggregate payments of more than $110M” Lytix is entitled to receive an up-front payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of more […]
